<DOC>
	<DOCNO>NCT00904657</DOCNO>
	<brief_summary>The study conduct : - investigate influence sunitinib ( study drug ) plasma biomarkers VEGF-A , VEGF-C , soluble VEGFR-2 , soluble VEGFR-3 ( vessel endothelial growth factor ) blood pressure ; - generate pharmacokinetic/pharmacodynamic model sunitinib use biomarkers .</brief_summary>
	<brief_title>An Explorative Study Pharmacokinetics Pharmacodynamics Sunitinib Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Caucasian Male/Female Age : 1855 year Body weight 60 kg high , Body Mass Index 19 27 kg/m2 Considered healthy basis extensive prestudy screen Willing capable confirm write consent enrolment ample information provide Ongoing heal wound parenchymal tissue require angiogenesis Any skin abnormality and/or neurodermatitis /or chronic skin disease A history haemorrhage A history gastrointestinal event persist clinical relevance A history pancreatitis History cerebrovascular accident transient ischemic attack seizures History pulmonary embolism History venous thromboembolic event History hypertension A history cardiac event within 12 month prior sunitinib administration myocardial infarction ( include severe/unstable angina ) , coronary/peripheral artery bypass graft Any relevant clinical abnormality ( base extensive medical history , amination , vital sign 12lead ECG ) Inadequate cardiac function [ leave ventricular ejection fraction ( LVEF ) &lt; low limit normal ( LLN ) assess echocardiography ( ECHO ) ] A history surgical abdominal intervention ( include appendectomy ) peritonitis Bronchial asthma , COPD , actual obstructive bronchitis Hypothyroidism /hyperthyroidism Cardiac insufficiency Liver disease Cardiac dysrhythmia ( e.g. , prolongation QT interval ) Diabetes mellitus Chronic infection Relevant acute infection actual therapyrequiring allergy ( include drug allergy ) within last two week Suspicion hypersensitivity sunitinib excipients Any clinically relevant laboratory abnormality Subjects receive medication within 2 week prior study start study ( exception possible upon decision Principal Investigator , e.g. , paracetamol ( acetaminophen ) single dose acute pain topical aciclovir herpes simplex ) Subjects take drug long halflife ( &gt; 24 hour ) within four week first trial day Subjects receive chronic drug treatment ( &gt; 3 day ) within eight week first trial day Subjects participate clinical trial within last 3 month start present study Subjects donate blood plasma within last 12 week start present study Subjects smoke , i.e. , subject smoke one cigarette last six month Subjects know suspected ( social ) drug dependent , incl . drink 30 g alcohol per day Subjects history alcohol recreational drug addiction Subjects history severe disease might interfere study objective ( e.g . psychiatric disease , epilepsy ) Subjects willing able abstain alcohol , methylxanthinecontaining beverage food , grapefruit flesh/juice 72 hour first study drug administration 2 week last study drug administration Subjects adhere special diet ( e.g. , vegetarian ) lifestyle ( include work night extreme physical activity competitive sport weight lift ) might interfere investigation Subjects planning elective hospital treatment within two month last intake trial medication Subjects know suspect comply study directives and/or know suspect reliable trustworthy Subjects know suspect capable understanding evaluate information give part formal information policy ( informed consent ) , particular regard foreseeable risk discomfort expose Subjects anticipate problem successfully place indwell venous catheter forearm Female subject : positive result pregnancy test pregnant lactate woman subject use agree use appropriate contraceptive method study two month study Male subject : accept procreate child study two month study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>pharmacokinetic/pharmacodynamic modeling</keyword>
	<keyword>biomarkers ( growth factor ) possible tool drug effect</keyword>
</DOC>